An update from SkinBioTherapeutics ( (GB:SBTX) ) is now available.
SkinBioTherapeutics announced the exercise of warrants by David Brierwood, reducing the company’s debt from £950,000 to £600,000 following their acquisition of Bio-Tech Solutions Limited. The new ordinary shares will be admitted to AIM, adjusting the total issued shares to 231,725,383. CEO Stuart Ashman highlighted the successful integration of Bio-Tech Solutions, which aligns with expectations and will contribute to upcoming financial results.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company concentrated on skin health, utilizing its proprietary technology, SkinBiotix®, developed by the dermatology team at the University of Manchester. The company targets the skin healthcare market through various pillars, focusing on cosmetic skincare and food supplements like AxisBiotix-Ps™ for psoriasis, and has partnerships like the one with Croda plc. It also expands through acquisitions in complementary skincare areas.
YTD Price Performance: 9.46%
Average Trading Volume: 841,458
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £46.26M
See more data about SBTX stock on TipRanks’ Stock Analysis page.